首页> 外文期刊>American Journal of Cancer Research >Single oral dose acute and subacute toxicity of a c-MET tyrosine kinase inhibitor and CDK 4/6 inhibitor combination drug therapy
【24h】

Single oral dose acute and subacute toxicity of a c-MET tyrosine kinase inhibitor and CDK 4/6 inhibitor combination drug therapy

机译:C-Met酪氨酸激酶抑制剂和CDK 4/6抑制剂组合药物治疗的单一口服剂量急性和亚急性毒性

获取原文
           

摘要

c-MET inhibitor, crizotinib, and CDK 4/6 inhibitor, palbociclib, have been evaluated in combination as cancer treatment in vitro. Because the toxicological data for the combination of these drugs is limited, we investigated the toxicity of the crizotinib and palbociclib combination in 80 ICR (CD-1) mice (average age = ~20 weeks). Treatments were arranged as a 2 × 2 × 2 factorial and included sex (female vs. male), crizotinib (0 or 4 mg), and palbociclib (0 or 1 mg). Drugs were administered to mice by oral gavage 24 hours (n = 40) and 7 days (n = 40) prior to the collection of blood and tissue samples to determine serum chemistry, hematology, and histopathology. After dosing, each study group of mice was observed acutely (24 hrs) and subacutely (7 days) for any clinical changes associated with toxicity from the drugs. Serum chemistry, hematological effects, and selected histological tissue samples of each animal immediately after euthanasia were analyzed at the end of the study. No significant abnormalities or changes in the clinical signs, body and organ weight, or gross and histopathological evaluations were observed. Although within the normal reference range, there was an elevation in the red blood cells (P = 0.05) from 24-hour crizotinib- and palbociclib-treated mice (both males and females), which contrasted with the typical anemia observed in palbociclib-treated patients. Administration of the crizotinib and palbociclib combination resulted in an elevation in the ALT liver enzyme (P = 0.05) in the 24-hour treated group (both male and female), but the levels were within the normal ranges of the mice. Overall, serum chemistry and hematology did not reach significant abnormal levels in any of the acute- or subacute-treated groups. The results of this study confirmed that the combination of crizotinib and palbociclib at the given doses did not cause significant treatment-related toxicities in mice.
机译:C-Met抑制剂,克里齐替尼和CDK 4/6抑制剂,帕尔巴古霉菌组合于体外作为癌症治疗。由于这些药物组合的毒理学数据是有限的,因此我们研究了克里齐替尼和帕尔巴发现组合在80克(CD-1)小鼠(平均年龄=〜20周)的毒性。处理被安排为2× 2× 2因子和包括性别(女性与男性),克里齐替尼(0或4毫克)和Palbociclib(0或1mg)。在收集血液和组织样品之前,通过口服饲养24小时(n = 40)和7天(n = 40)给小鼠施用于小鼠,以确定血清化学,血液学和组织病理学。给药后,每种研究小鼠急性(24小时)和亚缺乏(7天),以毒性与药物毒性相关的任何临床变化。在研究结束时分析了在Euthanasia后立即进行了每只动物的血清化学,血液学作用和选择的组织学组织样本。观察到临床症状,身体和器官重量或粗糙和组织病理学评估无明显异常或变化。虽然在正常参考范围内,从24小时屈曲和帕尔巴发现治疗的小鼠(男性和女性)的红细胞(P = 0.05)中存在升高,这与观察到在帕尔伯科基治疗的典型贫血中形成鲜明对比耐心。在24小时处理基团(雄性和雌性)中,克里齐替尼和帕尔巴昔米氏组合的施用导致ALT肝酶(P = 0.05)升高,但水平在小鼠的正常范围内。总体而言,血清化学和血液学在任何急性或亚级治疗组中没有达到显着的异常水平。本研究的结果证实,在给定剂量的克里齐替尼和帕尔巴癌的组合没有造成小鼠的显着治疗相关的毒性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号